In vitro reconstitution of complexes between pro-matrix metalloproteinase-9 and the proteoglycans serglycin and versican

FEBS Journal

Volumn 280, Issue 12, 2013, Pages 2870-2887

  Malla, Nabin ^a   Berg, Eli ^a   Theocharis, Achilleas D ^b   Svineng, Gunbjørg ^a   Uhlin Hansen, Lars ^a   Winberg, Jan Olof ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

chondroitin sulfate proteoglycan; gelatinase B; in vitro reconstitution; MMP 9; ProMMP 9 complexes

Indexed keywords

CHONDROITIN ABC LYASE; DODECYL SULFATE SODIUM; ENZYME PRECURSOR; GELATIN; MESSENGER RNA; MONOMER; POLYMER; PROMATRIX METALLOPROTEINASE 9; PROMATRIX METALLOPROTEINASE 9 PROTEOCHONDROITIN SULFATE HETEROMER; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; SERGLYCIN; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRITON X 100; UNCLASSIFIED DRUG; VERSICAN;

ARTICLE; CELL STIMULATION; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISULFIDE BOND; ENZYME BINDING; ENZYME RECONSTITUTION; ENZYME STABILITY; HEMOPEXIN DOMAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR SIZE; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PURIFICATION;

CELL LINE, TUMOR; CHONDROITIN SULFATES; CYSTINE; DETERGENTS; ENZYME PRECURSORS; ENZYME STABILITY; GELATIN; HUMANS; HYDROGEN-ION CONCENTRATION; MATRIX METALLOPROTEINASE 9; MULTIPROTEIN COMPLEXES; OCTOXYNOL; PROTEIN BINDING; PROTEOGLYCANS; SODIUM CHLORIDE; SODIUM DODECYL SULFATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VERSICANS; VESICULAR TRANSPORT PROTEINS;

EID: 84878758741     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12291     Document Type: Article

References (64)

1. Butler GS, &, Overall CM, (2009) Updated biological roles for matrix metalloproteinases and new 'intracellular' substrates revealed by degradomics. Biochemistry 48, 10830-10845.
2. Flannery CR, (2006) MMPs and ADAMTSs: functional studies. Front Biosci 11, 544-569.
3. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, &, Winberg JO, (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278, 28-45.
4. Nagase H, Visse R, &, Murphy G, (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562-573.
5. Ra HJ, &, Parks WC, (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26, 587-596.
6. Strongin AY, (2006) Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 25, 87-98.
7. Cawston TE, &, Wilson AJ, (2006) Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20, 983-1002.
8. Malemud CJ, (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11, 1696-1701.
9. Gialeli C, Theocharis AD, &, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
10. Descamps FJ, Martens E, Ballaux F, Geboes K, &, Opdenakker G, (2004) In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J Pathol 204, 555-561.
11. Descamps FJ, Martens E, Proost P, Starckx S, Van den Steen PE, Van Damme J, &, Opdenakker G, (2005) Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens βB1 crystallin. FASEB J 19, 29-35.
12. Starckx S, Van den Steen PE, Verbeek R, van Noort JM, &, Opdenakker G, (2003) A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys αB-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 141, 47-57.
13. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, &, Opdenakker G, (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37, 375-536.
14. Fadnes B, Hadler-Olsen E, Sylte I, Uhlin-Hansen L, &, Winberg JO, (2012) Matrix metalloproteinase complexes and their biological significance. In Extracellular Matrix: Pathobiology and Signalling (, Karamanos NK, ed), pp. 291-314. DeGruyter, Berlin, Germany.
15. Murphy G, &, Nagase H, (2011) Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J 278, 2-15.
16. Malla N, Sjoli S, Winberg JO, Hadler-Olsen E, &, Uhlin-Hansen L, (2008) Biological and pathobiological functions of gelatinase dimers and complexes. Connect Tissue Res 49, 180-184.
17. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, &, Murphy G, (1995) Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 309, 299-306.
18. Collier IE, Krasnov PA, Strongin AY, Birkedal-Hansen H, &, Goldberg GI, (1992) Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase. J Biol Chem 267, 6776-6781.
19. Hornebeck W, Bellon G, &, Emonard H, (2005) Fibronectin type II (FnII)-like modules regulate gelatinase A activity. Pathol Biol (Paris) 53, 405-410.
20. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, &, Docherty AJ, (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 269, 6632-6636.
21. O'Farrell TJ, &, Pourmotabbed T, (1998) The fibronectin-like domain is required for the type V and XI collagenolytic activity of gelatinase B. Arch Biochem Biophys 354, 24-30.
22. Shipley JM, Doyle GA, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, &, Senior RM, (1996) The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem 271, 4335-4341.
23. Steffensen B, Wallon UM, &, Overall CM, (1995) Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 270, 11555-11566.
24. Strongin AY, Collier IE, Krasnov PA, Genrich LT, Marmer BL, &, Goldberg GI, (1993) Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 43, 158-162.
25. Xu X, Chen Z, Wang Y, Yamada Y, &, Steffensen B, (2005) Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J 392, 127-134.
26. Xu X, Wang Y, Lauer-Fields JL, Fields GB, &, Steffensen B, (2004) Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol 23, 171-181.
27. Goldberg GI, Strongin A, Collier IE, Genrich LT, &, Marmer BL, (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267, 4583-4591.
28. Hibbs MS, Hasty KA, Seyer JM, Kang AH, &, Mainardi CL, (1985) Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 260, 2493-2500.
29. Kjeldsen L, Johnsen AH, Sengelov H, &, Borregaard N, (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268, 10425-10432.
30. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, Massova I, Mobashery S, &, Fridman R, (2000) Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 275, 2661-2668.
31. Triebel S, Blaser J, Reinke H, &, Tschesche H, (1992) A 25 kDa α2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314, 386-388.
32. Winberg JO, Kolset SO, Berg E, &, Uhlin-Hansen L, (2000) Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 304, 669-680.
33. Winberg JO, Berg E, Kolset SO, &, Uhlin-Hansen L, (2003) Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem 270, 3996-4007.
34. Malla N, Berg E, Uhlin-Hansen L, &, Winberg JO, (2008) Interaction of pro-matrix metalloproteinase-9/proteoglycan heteromer with gelatin and collagen. J Biol Chem 283, 13652-13665.
35. Malla N, Berg E, Moens U, Uhlin-Hansen L, &, Winberg JO, (2011) Biosynthesis of promatrix metalloproteinase-9/chondroitin sulphate proteoglycan heteromer involves a Rottlerin-sensitive pathway. PLoS ONE 6, e20616.
36. Yan L, Borregaard N, Kjeldsen L, &, Moses MA, (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276, 37258-37265.
37. Schick BP, Gradowski JF, &, San Antonio JD, (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97, 449-458.
38. Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K, &, Miyasaka M, (1997) Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 272, 26714-26719.
39. Paroutis P, Touret N, &, Grinstein S, (2004) The pH of the secretory pathway: measurement, determinants, and regulation. Physiology 19, 207-215.
40. Chang MY, Chan CK, Braun KR, Green PS, O'Brien KD, Chait A, Day AJ, &, Wight TN, (2012) Monocyte-to-macrophage differentiation: synthesis and secretion of a complex extracellular matrix. J Biol Chem 287, 14122-14135.
41. Makatsori E, Lamari FN, Theocharis AD, Anagnostides S, Hjerpe A, Tsegenidis T, &, Karamanos NK, (2003) Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res 23, 3303-3309.
42. Øynebråten I, Hansen B, Smedsrød B, &, Uhlin-Hansen L, (2000) Serglycin secreted by leucocytes is efficiently eliminated from the circulation by sinusoidal scavanger endothelial cells in the liver. J Leukoc Biol 67, 183-188.
43. Kolset SO, &, Zernichow L, (2008) Serglycin and secretion in human monocytes. Glycoconj J 25, 305-311.
44. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, et al,. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281, 35116-35128.
45. Theocharis AD, Tsolakis I, Hjerpe A, &, Karamanos NK, (2003) Versican undergoes specific alterations in the fine molecular structure and organization in human aneurysmal abdominal aortas. Biomed Chromatogr 17, 411-416.
46. Creighton TE, (1989) Disulphide bonds between cysteine residues. In Protein Structure: A Practical Approach (, Creighton TE, ed), pp. 155-168. IRL Press, Oxford.
47. Jaenicke R, &, Rudolph R, (1989) Folding Proteins. In Protein Structure: A Practical Approach (, Creighton TE, ed), pp. 191-223. IRL Press, Oxford.
48. Cha H, Kopetzki E, Huber R, Lanzendorfer M, &, Brandstetter H, (2002) Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol 320, 1065-1079.
49. Murphy G, &, Crabbe T, (1995) Gelatinases A and B. Methods Enzymol 248, 470-484.
50. Pourmotabbed T, (1994) Relation between substrate specificity and domain structure of 92-kDa type IV collagenase. Ann N Y Acad Sci 732, 372-374.
51. Zhang L, Yang M, Yang D, Cavey G, Davidson P, &, Gibson G, (2010) Molecular interactions of MMP-13 C - terminal domain with chondrocyte proteins. Connect Tissue Res 51, 230-239.
52. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
53. Lord MS, &, Whitelock JM, (2013) Recombinant production of proteoglycans and their bioactive domains. FEBS J 280, 2490-2510.
54. Tocchi A, &, Parks WC, (2013) Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J 280, 2332-2341.
55. Biederbick A, Licht A, &, Kleene R, (2003) Serglycin proteoglycan is sorted into zymogen granules of rat pancreatic acinar cells. Eur J Cell Biol 82, 19-29.
56. Kolset SO, &, Pejler G, (2011) Serglycin: a structural and functional chameleon with wide impact on immune cells. J Immunol 187, 4927-4933.
57. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, et al,. (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71, 3162-3172.
58. Meen AJ, Oynebraten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, &, Kolset SO, (2011) Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROα/CXCL1. J Biol Chem 286, 2636-2647.
59. Skliris A, Labropoulou VT, Papachristou DJ, Aletras A, Karamanos NK, &, Theocharis AD, (2013) Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J 280, 2342-2352.
60. Farndale RW, Buttle DJ, &, Barrett AJ, (1986) Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883, 173-177.
61. Loennechen T, Mathisen B, Hansen J, Lindstad RI, El-Gewely SA, Andersen K, Maelandsmo GM, &, Winberg JO, (2003) Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol 66, 2341-2353.
62. Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, &, Winberg JO, (2003) S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis 20, 701-711.
63. Hattori S, Fujisaki H, Kiriyama T, Yokoyama T, &, Irie S, (2002) Real-time zymography and reverse zymography: a method for detecting activities of matrix metalloproteinases and their inhibitors using FITC-labeled collagen and casein as substrates. Anal Biochem 301, 27-34.
64. -ΔΔCT. Methods 25, 402-408.